CY1109064T1 - Ενωσεις aminoσακχαρου, γλυκοσαμινογλυκανης ή τυπου γλυκοσαμινογλυκανης, και s-αδενοσυλμεθειονινη - Google Patents

Ενωσεις aminoσακχαρου, γλυκοσαμινογλυκανης ή τυπου γλυκοσαμινογλυκανης, και s-αδενοσυλμεθειονινη

Info

Publication number
CY1109064T1
CY1109064T1 CY20091100511T CY091100511T CY1109064T1 CY 1109064 T1 CY1109064 T1 CY 1109064T1 CY 20091100511 T CY20091100511 T CY 20091100511T CY 091100511 T CY091100511 T CY 091100511T CY 1109064 T1 CY1109064 T1 CY 1109064T1
Authority
CY
Cyprus
Prior art keywords
composition
sulfate
glycosaminoglycan
salts
connective tissue
Prior art date
Application number
CY20091100511T
Other languages
English (en)
Inventor
Robert W Henderson
Todd Henderson
Tarek Hammad
Original Assignee
Nutramax Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25296238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109064(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutramax Laboratories, Inc. filed Critical Nutramax Laboratories, Inc.
Publication of CY1109064T1 publication Critical patent/CY1109064T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Μια σύνθεση για την προστασία, θεραπεία και αποκατάσταση και για τη μείωση της φλεγμονής συνδετικού ιστού σε θηλαστικά και μια μέθοδος για την προστασία, θεραπεία συνδετικού ιστού σε θηλαστικά με τη χορήγηση της σύνθεσης. Η σύνθεση περιλαμβάνει τουλάχιστον δυο ενώσεις που επιλέγονται από S-Αδενοσυλμεθειovίνη (SAM), ένα αμινοσάκχαρο που επιλέγεται από την ομάδα που αποτελείται από γλυκοσαμίνη, άλατα γλυκοσαμίνης, υδροχλωρική γλυκοσαμίνη, γαλακτοσαμίνη, Ν-ακετυλογλυκοσαμίνη, και θραύσματα, μίγματα ή άλατα αυτών, και μια γλυκοσαμινογλυκάνη ή ένωση τύπου γλυκοσαμινογλυκάνης που επιλέγεται από την ομάδα που αποτελείται από χονδροϊτίνη, άλατα χονδροϊτίνης, υαλουρονικό οξύ, γλυκαρονικό οξύ, ιδουρονικό οξύ, θειική κερατάνη, θειική κεράτινη, θειική ηπαράνη, θειική δερμάτινη, PPS, PPS νατρίου, PPS ασβεστίου, υπερθειικά GAGs, και θραύσματα, άλατα, και μίγματα αυτών. Η σύνθεση προαιρετικά περιλαμβάνει μαγγάνιο το οποίο προάγει την παραγωγή μήτρας συνδετικού ιστού. Η σύνθεση περιλαμβάνει επίσης προαιρετικά δότες μεθυλίου ή συμπαράγοντες δοτών μεθυλίου, όπως βιταμίνη Β12, βιταμίνη Β6, φολικό οξύ, διμεθυλογλυκίνη ή τριμεθυλογλυκίνη, και βεταΐνη.
CY20091100511T 1997-04-28 2009-05-13 Ενωσεις aminoσακχαρου, γλυκοσαμινογλυκανης ή τυπου γλυκοσαμινογλυκανης, και s-αδενοσυλμεθειονινη CY1109064T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/845,852 US6255295B1 (en) 1996-12-23 1997-04-28 Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue
EP98915591A EP0979090B1 (en) 1997-04-28 1998-04-17 Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine

Publications (1)

Publication Number Publication Date
CY1109064T1 true CY1109064T1 (el) 2014-07-02

Family

ID=25296238

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100511T CY1109064T1 (el) 1997-04-28 2009-05-13 Ενωσεις aminoσακχαρου, γλυκοσαμινογλυκανης ή τυπου γλυκοσαμινογλυκανης, και s-αδενοσυλμεθειονινη

Country Status (13)

Country Link
US (1) US6255295B1 (el)
EP (2) EP1849471B1 (el)
AT (2) ATE425757T1 (el)
AU (1) AU747595B2 (el)
CA (3) CA2539919A1 (el)
CY (1) CY1109064T1 (el)
DE (2) DE69842021D1 (el)
DK (1) DK0979090T3 (el)
ES (2) ES2357255T3 (el)
HK (1) HK1114774A1 (el)
NZ (1) NZ500025A (el)
PT (1) PT979090E (el)
WO (1) WO1998048816A1 (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010000472A1 (en) * 1998-02-27 2001-04-26 Nutramax Laboratories, Inc. L-ergothioneine, milk thistle, and s-adenosylmethionine for the prevention, treatment and repair of liver damage
WO1999062524A1 (en) * 1998-06-04 1999-12-09 Nutramax Laboratories, Inc. Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue
DK1083929T3 (da) * 1998-06-05 2007-06-11 Nutramax Lab Inc Anvendelse af anabolske stoffer
EP1762247A1 (en) * 1998-06-05 2007-03-14 Nutramax Laboratories, Inc. The use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissue in humans and animals
US6656925B2 (en) * 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
US20020018787A1 (en) 1999-05-21 2002-02-14 Roger V. Kendall Methods and compositions for modulating immune response and for the treatment of inflammatory disease
AU761829B2 (en) * 1999-07-21 2003-06-12 Bomac Laboratories Limited Compositions addressing inflammation and/or degenerative disorders
US6524609B1 (en) * 1999-08-18 2003-02-25 Nutri-Vet, Llc Treating arthritis in animals with dietary supplements
AU7863400A (en) * 1999-10-08 2001-04-23 Pharmnseas, Inc. Nutraceutical products containing same and dietary supplements and method of manufacture and use thereof
DE20004010U1 (de) 2000-03-02 2000-06-21 Febena Pharma GmbH, 50825 Köln Diätische Zusammensetzung mit einem Gehalt an Glycosaminoglycanen
US20050282774A1 (en) * 2000-10-31 2005-12-22 Eek Bjorn C Method and pharmaceutical to treat spinal discs
AU2002243630A1 (en) 2001-01-23 2002-08-06 Massachusetts Institute Of Technology Solid- and solution -phase synthesis of heparin and other glycosaminoglycans
US6916492B2 (en) 2001-03-30 2005-07-12 Council Of Scientific & Industrial Research Natural nontoxic multicolor fluorescent protein dye from a marine invertebrate, compositions containing the said dye and its uses
US6689391B2 (en) 2001-03-30 2004-02-10 Council Of Scientific & Industrial Research Natural non-polar fluorescent dye from a non-bioluminescent marine invertebrate, compositions containing the said dye and its uses
BRPI0101486B1 (pt) * 2001-04-17 2017-09-19 Cristália Produtos Químicos Farmacêuticos Ltda. Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns
US20030134825A1 (en) * 2002-01-03 2003-07-17 Robert Bahoshy Food product supplemented with proteoglycan precursors
US20030138543A1 (en) * 2002-01-03 2003-07-24 Bradley T. Baumann Food product supplemented with proteoglycan precursors
US7387796B2 (en) * 2002-01-30 2008-06-17 Hebert Rolland F Stable compositions of S-adenosyl-l-methionine with dextran
US7504115B2 (en) * 2002-02-15 2009-03-17 Ocean Nutrition Canada Limited Shark cartilage extracts and use thereof for immunomodulation
US20030170374A1 (en) * 2002-03-05 2003-09-11 Robert Bahoshy Condiments including nutritional supplements
EP1496917B1 (en) * 2002-04-19 2005-12-07 Astion Development A/S Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
US7504387B2 (en) * 2002-10-16 2009-03-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
US7485629B2 (en) * 2002-10-16 2009-02-03 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treatment of joint damage
DE10260958A1 (de) * 2002-12-20 2004-07-08 Sustech Gmbh & Co. Kg Kompositmaterialien aus Calciumverbindungen und Glucuronsäure- und/oder Iduronsäurehaltigen Polysacchariden
US6946551B2 (en) * 2003-03-12 2005-09-20 New Life Resources, Llc Preparation of hyaluronic acid from eggshell membrane
US20040180025A1 (en) * 2003-03-12 2004-09-16 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US20080063677A1 (en) * 2004-03-10 2008-03-13 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
US8377904B2 (en) * 2004-02-09 2013-02-19 Hill's Pet Nutrition, Inc. Composition and method for use in cartilage affecting conditions
US20050176807A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
US20050176674A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
US8580315B2 (en) * 2004-03-10 2013-11-12 Esm Technologies, Llc Anti-inflammatory activity of eggshell membrane and processed eggshell membrane preparations
WO2007014155A2 (en) * 2005-07-22 2007-02-01 Trf Pharma, Inc. Method for treating sickle cell disease and sickle cell disease sequelae
US9492381B1 (en) 2005-11-10 2016-11-15 Reyn Pharma, Llc Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis
US8598144B1 (en) 2005-11-10 2013-12-03 Reyn Pharma, Llc Method of administering hyaluronan formulation for the amelioration of osteoarthritis
US20070243218A1 (en) * 2006-04-03 2007-10-18 Ellinghuysen Jerry A Stabilized pentosan polysulfate (PPS) formulations and methods of analyzing them
JP5175481B2 (ja) * 2006-10-23 2013-04-03 エーザイフード・ケミカル株式会社 軟骨再生促進剤
WO2008154178A1 (en) * 2007-06-06 2008-12-18 Novus International Inc. Dietary supplements for promotion of growth, repair, and maintenance of bone and joints
US7947662B2 (en) * 2008-02-20 2011-05-24 Gnosis S.P.A. Folates, compositions and uses thereof
US8163716B1 (en) 2008-06-30 2012-04-24 Smith James D Method of administering hyaluronan formulation for the amelioration of osteophytes
US8178511B1 (en) 2008-07-02 2012-05-15 Smith James D Method of administering hyaluronan formulation for the amelioration of osteopenia
US9180089B2 (en) * 2009-09-23 2015-11-10 Glenpharma Ab Compositions and methods for inducing or enhancing connective tissue repair
FR2996137B1 (fr) * 2012-10-01 2017-10-27 Sp2L Composition comprenant de l'acide hyaluronique, du manganese et de la vitamine c
EP3873415A1 (en) 2018-11-02 2021-09-08 Unilever Global Ip Limited Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same
IT202100030935A1 (it) 2021-12-09 2023-06-09 Fidia Farm Spa Compresse comprendenti condroitin solfato, glucosamina cloridrato e vitamina c per il trattamento di danni cartilaginei, tendinei, ossei

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3232836A (en) 1959-08-24 1966-02-01 Pfizer & Co C Facilitating healing of body surface wounds by intravenous administration of n-acetyl glucosamine, glucosamine, or pharmaceutically acceptable acid salts of glucosamine
US3371012A (en) 1964-08-07 1968-02-27 Seikagaku Kogyo Co Ltd Preservative for eye graft material
DE1792346C3 (de) 1968-08-22 1980-10-23 Rotta Research Laboratorium S.P.A., San Fruttuoso Di Monza, Mailand (Italien) Pharmazeutisches Präparat für die Behandlung von degenerativen Gelenkerkrankungen
IT1044707B (it) 1968-10-26 1980-04-21 Rotta Research Lab Procedimento per la preparazione di sali di glucosanina e preparati farmaceutici comprendenti detti sali di glucosamina come agenti attivi
JPS5027884A (el) 1973-07-12 1975-03-22
US4006224A (en) 1975-09-29 1977-02-01 Lescarden Ltd. Method and agent for treating inflammatory disorders of the gastrointestinal tract
US4378224A (en) 1980-09-19 1983-03-29 Nimni Marcel E Coating for bioprosthetic device and method of making same
US5180715A (en) 1980-11-17 1993-01-19 The Regents Of The University Of California Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate
US4486416A (en) 1981-03-02 1984-12-04 Soll David B Protection of human and animal cells subject to exposure to trauma
IT1137640B (it) 1981-08-24 1986-09-10 Bioresearch Srl Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo
IT1137892B (it) 1981-08-24 1986-09-10 Bioresearch Srl Sali stabili della s-adenosilmetionina,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo
US4473551A (en) 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
FR2543145B1 (fr) 1983-03-24 1986-10-17 Sanofi Sa Nouveaux sulfates de xylanes, leur procede de preparation et leur activite anti-thrombotique et hypolipemiante
IT1173990B (it) 1984-05-16 1987-06-24 Bioresearch Spa Sali stabili della solfo-adenosil-l-metionina (same) particolarmente adatti per uso parenterale
IT1173992B (it) 1984-05-16 1987-06-24 Bioresearch Spa Sali stabili della solfo-adenosil-l-metionina (same) particolarmente idonei per uso farmaceutico orale
US4711780A (en) 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
DE3422407A1 (de) 1984-06-16 1986-03-06 B. Braun Melsungen Ag, 3508 Melsungen Verwendung von heparinderivaten zur selektiven extrakorporalen praezipitation von low-density-lipoproteinen aus vollserum oder plasma
DE3432661A1 (de) 1984-09-05 1986-03-06 Albert Prof. Dr. 6907 Nußloch Landsberger Carcinom-therapeutikum
US4647453A (en) 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
FR2572731B1 (fr) 1984-11-07 1987-03-06 Sanofi Sa Nouveaux sulfates de xylanes de bas poids moleculaires, leur procede de preparation et leur activite antithrombotique et hypolipemiante par voie orale
SE8501723L (sv) 1985-04-09 1986-10-10 Pharmacia Ab Preparation att anvendas vid behandling av ledinflammation
US4707354A (en) 1985-06-17 1987-11-17 Alpen Tau, Inc. Mature skin treatment and protectant compositions and methods of using same
US4772591A (en) 1985-09-25 1988-09-20 Peritain, Ltd. Method for accelerated wound healing
DE3602670A1 (de) 1986-01-29 1987-07-30 Speck Ulrich Verwendung von n-acetylglucosamin zur therapie degenerativer gelenkprozesse und verwandter erkrankungen
US4983580A (en) 1986-04-04 1991-01-08 Allergan, Inc. Methods and materials for use in corneal wound healing
US4820693A (en) 1986-05-22 1989-04-11 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US4966890A (en) 1986-04-04 1990-10-30 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US5385938B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5091171B2 (en) 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5145841A (en) 1987-03-19 1992-09-08 Arthropharm Pty. Limited Anti-inflammatory compounds and compositions
US5668116A (en) 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
US5263984A (en) 1987-07-20 1993-11-23 Regen Biologics, Inc. Prosthetic ligaments
FR2609397B1 (fr) 1988-02-23 1991-12-13 Serobiologiques Lab Sa Utilisation d'une substance ou composition de nature glucidique comme principe actif d'une composition dermatologique et/ou cosmetologique et/ou pharmaceutique et/ou stimulante cellulaire, et composition contenant une telle substance ou composition de nature glucidique
US5510418A (en) 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
GB8900812D0 (en) 1989-01-14 1989-03-08 Univ Manchester Pharmaceutical method and compositions
FR2649982B1 (fr) 1989-07-20 1991-09-27 Inst Nat Sante Rech Med Membrane biologique artificielle
DE3942081A1 (de) 1989-12-20 1991-06-27 Behringwerke Ag Mittel zur verbesserung der wiederfindung von annexinen
US5141928B1 (en) 1989-12-20 1995-11-14 Brujo Inc Ophthalmic medication
US5514667A (en) 1990-11-05 1996-05-07 Arthropharm Pty. Limited Method for topical treatment of herpes infections
AU1052492A (en) 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
IT1260137B (it) 1992-04-17 1996-03-28 Alfa Wassermann Spa Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato
CA2122342A1 (en) 1992-09-04 1994-03-17 Hironori Kawabata Pharmaceutical composition
IT1264102B1 (it) 1993-03-29 1996-09-10 Alfa Wassermann Spa Processo per la sintesi di glicosaminoglicani semisintetici contenenti acido alfa-l-galatturonico sostituito con radicali
IT1264101B1 (it) 1993-03-29 1996-09-10 Alfa Wassermann Spa Processo per la sintesi di glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2
US5364845C1 (en) * 1993-03-31 2002-09-10 Nutramax Lab Inc Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue
US5691325A (en) 1994-01-14 1997-11-25 Sandyk; Reuven Method for ameliorating age-related disease conditions
US5597575A (en) 1994-06-06 1997-01-28 Breitbarth; Richard Composition for stimulating and inducing hair growth
US5639787A (en) 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer
AU721067B2 (en) * 1995-04-25 2000-06-22 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5643892A (en) 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases
EP0830351A1 (en) 1995-06-07 1998-03-25 Monsanto Company Process for preparing substituted polyazamacrocycles
GB2317109B (en) * 1996-08-28 2000-06-21 Farmsense A therapeutic composition for the treatment and repair of connective tissue in mammals

Also Published As

Publication number Publication date
DE69840668D1 (de) 2009-04-30
AU6973398A (en) 1998-11-24
DK0979090T3 (da) 2009-06-08
EP1849471A1 (en) 2007-10-31
ATE425757T1 (de) 2009-04-15
CA2539919A1 (en) 1998-11-05
EP1849471B1 (en) 2010-11-24
DE69842021D1 (de) 2011-01-05
CA2286552A1 (en) 1998-11-05
CA2286552C (en) 2007-10-30
WO1998048816A1 (en) 1998-11-05
HK1114774A1 (en) 2008-11-14
AU747595B2 (en) 2002-05-16
US6255295B1 (en) 2001-07-03
ES2357255T3 (es) 2011-04-20
CA2539696A1 (en) 1998-11-05
EP0979090A1 (en) 2000-02-16
NZ500025A (en) 2002-03-01
ATE489099T1 (de) 2010-12-15
ES2324565T3 (es) 2009-08-10
EP0979090B1 (en) 2009-03-18
PT979090E (pt) 2009-05-04
EP0979090A4 (en) 2000-10-18

Similar Documents

Publication Publication Date Title
CY1109064T1 (el) Ενωσεις aminoσακχαρου, γλυκοσαμινογλυκανης ή τυπου γλυκοσαμινογλυκανης, και s-αδενοσυλμεθειονινη
Kuo Practical aspects of hyaluronan based medical products
BR0214032A (pt) Método terapêutico para o tratamento de uma junta demonstrando degeneração de cartilagem articular, uso de uma solução aquosa estáve, viscosa e tamponada, método para reparar ou regenerar cartilagem em uma junta de mamìferos, e, uso de uma mistura de sulfato de condroitina e ácido hialurÈnico ou sais farmaceuticamente aceitáveis dos mesmos
TR199800353T1 (xx) Ameliyat sonras� adhasyon �nleyici biyo-malzemeler.
BR9608330A (pt) Copolìmero em bloco heterotelequélico e um método para a produção do mesmo.
BRPI0411340A (pt) conservante particulado de madeira e método para produzir o mesmo
IT1301994B1 (it) Derivati dell'acido ialuronico.
ITPD20050146A1 (it) Fillers riassorbibili costituiti da liposomi e acido ialuronico e o suoi derivati
CY1115215T1 (el) Παραγωγα αμιδιου υαλουρονικου οξεος στην εκφυλιστικη οστεοαρθροπαθεια
BR9609534B1 (pt) processo para preparar uma composição de gel de polissacarìdeo biocompatìvel reticulada, e, composição de gel de polissacarìdeo.
SE9504495D0 (sv) Linjär blockpolymer innefattande urea- och uretangrupper, förfarande för framställning av linjära blockpolymerer samt användning av blockpolymererna som implantat
CA2159591A1 (en) Aminosugar and Glycosaminoglycan Composition for the Treatment and Repair of Connective Tissue
BR0009651A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
ATE272654T1 (de) Neue vernetzte derivate der hyaluronsäure.
BR9608041A (pt) Oligossacarídeo sulfatado processo para o tratamento anti-angiogênico anti-metastático e/ou anti-inflamatório de um paciente humano ou outro paciente animal de sangue quente uso de um oligossacarídeo e composição farmacêutica ou veterinária para tratamento anti-angiogênico anti-metastático e/ou anti-inflamatório
PT82198B (pt) Processo de producao de sulfato de heparano e sulfato de dermatano, naturais, em forma substancialmente pura e de composicoes farmaceuticas que os contem
CY1105531T1 (el) Ρυθμιστες πολυσακχαριδιων και χρησεις αυτων
BR0010380A (pt) Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos
BR0215210A (pt) Composição de poliuretano termoplástica extrusada, e, processo para a preparação de poliuretano termoplástico
ATE119547T1 (de) Oligosaccharide mit antiatherosclerotischer wirkung.
BRPI0417750A (pt) composto da fórmula; composição farmacêutica ou veterinária; uso do composto, e método para prevenção e tratamento na área de glicosaminoglicano (gag) miméticos
ATE220410T1 (de) Glykosaminoglykane mit hoher antithrombotischer wirkung
TW200704403A (en) Dilution resistant viscoelastic compositions
BR0010381A (pt) Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina
ITMI912309A1 (it) Oligosaccaridi di dermatan solfato, processo per la loro produzione e relative composizioni farmaceutiche.